Abbisko Cayman Ltd
HKEX:2256

Watchlist Manager
Abbisko Cayman Ltd Logo
Abbisko Cayman Ltd
HKEX:2256
Watchlist
Price: 4.33 HKD -0.23% Market Closed
Market Cap: 2.9B HKD
Have any thoughts about
Abbisko Cayman Ltd?
Write Note

Abbisko Cayman Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Abbisko Cayman Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Abbisko Cayman Ltd
HKEX:2256
Cash from Operating Activities
-ÂĄ444.7m
CAGR 3-Years
-54%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-ÂĄ7.8B
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Operating Activities
ÂĄ555.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
ÂĄ1.5B
CAGR 3-Years
49%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Operating Activities
ÂĄ3.3B
CAGR 3-Years
-29%
CAGR 5-Years
24%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Operating Activities
ÂĄ2B
CAGR 3-Years
66%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Abbisko Cayman Ltd
Glance View

Market Cap
3B HKD
Industry
Biotechnology

Abbisko Cayman Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of drugs and small molecule oncology therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-10-13. The firm is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The firm owns two Core Product Candidates, ABSK011 and ABSK091, and 12 other pipeline product candidates. ABSK011 is a potent and highly selective small molecule inhibitor of fibroblast growth factor receptor 4 (FGFR4). ABSK091 is a molecularly targeted product candidate and a highly potent and selective inhibitor of FGFR subtypes 1, 2 and 3. The Company’s products are primarily being developed for hepatocellular carcinoma (HCC), urothelial cancer (UC) and gastric cancer (GC).

Intrinsic Value
2.41 HKD
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Abbisko Cayman Ltd's Cash from Operating Activities?
Cash from Operating Activities
-444.7m CNY

Based on the financial report for Dec 31, 2023, Abbisko Cayman Ltd's Cash from Operating Activities amounts to -444.7m CNY.

What is Abbisko Cayman Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-54%

Over the last year, the Cash from Operating Activities growth was -29%. The average annual Cash from Operating Activities growth rates for Abbisko Cayman Ltd have been -54% over the past three years .

Back to Top